Search

Your search keyword '"Chen, Pei-Jer"' showing total 1,366 results
Start Over Author "Chen, Pei-Jer" Language english
1,366 results on '"Chen, Pei-Jer"'

2. Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Author

Liu, Chen-Hua, Chang, Yu-Ping, Fang, Yu-Jen, Cheng, Pin-Nan, Chen, Chi-Yi, Kao, Wei-Yu, Lin, Chih-Lin, Yang, Sheng-Shun, Shih, Yu-Lueng, Peng, Cheng-Yuan, Tsai, Ming-Chang, Huang, Shang-Chin, Su, Tung-Hung, Tseng, Tai-Chung, Liu, Chun-Jen, Chen, Pei-Jer, and Kao, Jia-Horng

Published
2024
Full Text
View/download PDF

14. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie

Published
2023
Full Text
View/download PDF

15. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

Author

Razavi, Homie A., Buti, Maria, Terrault, Norah A., Zeuzem, Stefan, Yurdaydin, Cihan, Tanaka, Junko, Aghemo, Alessio, Akarca, Ulus S., Al Masri, Nasser M., Alalwan, Abduljaleel M., Aleman, Soo, Alghamdi, Abdullah S., Alghamdi, Saad, Al-Hamoudi, Waleed K., Aljumah, Abdulrahman A., Altraif, Ibrahim H., Asselah, Tarik, Ben-Ari, Ziv, Berg, Thomas, Biondi, Mia J., Blach, Sarah, Braga, Wornei S.M., Brandão-Mello, Carlos E., Brunetto, Maurizia R., Cabezas, Joaquin, Cheinquer, Hugo, Chen, Pei-Jer, Cheon, Myeong-Eun, Chuang, Wan-Long, Coffin, Carla S., Coppola, Nicola, Craxi, Antonio, Crespo, Javier, De Ledinghen, Victor, Duberg, Ann-Sofi, Etzion, Ohad, Ferraz, Maria Lucia G., Ferreira, Paulo R.A., Forns, Xavier, Foster, Graham R., Gaeta, Giovanni B., Gamkrelidze, Ivane, García-Samaniego, Javier, Gheorghe, Liliana S., Gholam, Pierre M., Gish, Robert G., Glenn, Jeffrey, Hercun, Julian, Hsu, Yao-Chun, Hu, Ching-Chih, Huang, Jee-Fu, Janjua, Naveed, Jia, Jidong, Kåberg, Martin, Kaita, Kelly D.E., Kamal, Habiba, Kao, Jia-Horng, Kondili, Loreta A., Lagging, Martin, Lázaro, Pablo, Lazarus, Jeffrey V., Lee, Mei-Hsuan, Lim, Young-Suk, Marotta, Paul J., Navas, Maria-Cristina, Naveira, Marcelo C.M., Orrego, Mauricio, Osiowy, Carla, Pan, Calvin Q., Pessoa, Mário G., Raimondo, Giovanni, Ramji, Alnoor, Razavi-Shearer, Devin M., Razavi-Shearer, Kathryn, Ríos-Hincapié, Cielo Y., Rodríguez, Manuel, Rosenberg, William M.C., Roulot, Dominique M., Ryder, Stephen D., Safadi, Rifaat, Sanai, Faisal M., Santantonio, Teresa A., Sarrazin, Christoph, Shouval, Daniel, Tacke, Frank, Tergast, Tammo L., Villalobos-Salcedo, Juan Miguel, Voeller, Alexis S., Yang, Hwai-I, Yu, Ming-Lung, and Zuckerman, Eli

Published
2023
Full Text
View/download PDF

35. Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies.

Author

Chen, Pei‐Jer

Subjects
*HEPATITIS B, *CHRONIC hepatitis B, *HEPATITIS B vaccines, *VACCINATION, *THERAPEUTICS, *VACCINE hesitancy
Abstract

Chronic hepatitis B (CHB) was, and still is, a prevalent liver disease in the world, especially high in the Asia‐Pacific areas. With the advent of preventive vaccines and effective viral suppression drugs and active implementations, CHB has gradually become under control. The world‐wide prevalence reduces from 4.2% in 1980 to 3.2% in 2020 study. CHB patients receiving long‐term antiviral therapies significantly improve the clinical outcomes, saving from end‐stage liver diseases. Despite of these impressive progresses, to meet the WHO sustained development goals (SDG) for CHB control, a 90% reduction of incidence and a 65% reduction of mortality in year 2030, there is still a long way to go. In this review, four ongoing approaches have been proposed: (i) A continuous monitoring of long‐term vaccine efficacy in vaccinated populations; (ii) consolidating the hepatitis B virus vaccination program against vaccine hesitancy and limited resources; (iii) rolling‐out current oral antivirals to more CHB patients not only for diseases treatment but also for infection preventions; and (iv) development of curative therapies, both friendly‐to‐dispense and affordable. A coherent and persevere efforts by the society may succeed and achieve the SDG for CHB in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping.

Author

Chang, Yu‐Ping, Huang, Chiuan‐Bo, Su, Tung‐Hung, Liu, Chun‐Jen, Tseng, Tai‐Chung, Huang, Shang‐Chin, Chen, Pei‐Jer, Kao, Jia‐Horng, and Liu, Chen‐Hua

Subjects
HEPATITIS C virus, GENOTYPES, NUCLEOTIDE sequencing, VIRAL load
Abstract

Comparison of diagnostic accuracy for commercial hepatitis C virus (HCV) genotyping (Abbott RealTime HCV Genotyping II, Roche Cobas Genotyping) and investigational Abbott HCV Genotype plus RUO assays designed to discriminate genotype (GT)‐1a, 1b or 6 in cases of ambiguous GT from the Abbott commercial assay remains limited. 743 HCV‐viremic samples were subjected to analysis using Abbott and Roche commercial as well as Abbott HCV Genotype plus RUO assays. Next‐generation sequencing (NGS) targeting core region was employed as the reference standard. Diagnostic accuracy was reported as the number of participants (percentages) along with 95% confidence intervals (CIs). Using NGS, 741 samples (99.7%) yielded valid genotyping results. The diagnostic accuracies were 97.6% (95% CI: 96.1%–98.5%) and 95.3% (95% CI: 93.4%–96.6%) using Abbott and Roche commercial assays (p = 0.0174). Abbott commercial assay accurately diagnosed HCV GT‐6a and 6w, whereas Roche commercial assay accurately diagnosed HCV GT‐6a. Both assays demonstrated low accuracies for HCV GT‐6b, 6e, 6g, and 6n. Abbott HCV Genotype plus RUO assay discriminated 13 of the 14 samples (92.9%; 95% CI: 64.2%–99.6%) that yielded ambiguous GT. Both assays were capable of diagnosing mixed HCV infections when the minor genotype comprised >8.4% of the viral load. The diagnostic performance of commercial HCV genotyping assays is commendable. Abbott assay demonstrated superior performance compared to Roche assay in diagnosing HCV GT‐6. Abbott HCV Genotype plus RUO assay aids in discriminating ambiguous GT. Both commercial assays are proficient in diagnosing mixed HCV infections at a cut‐off viral load of 8.4% in minor genotype. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals.

Author

Liu, Chen‐Hua, Chang, Yu‐Ping, Lee, Ji‐Yuh, Chen, Chi‐Yi, Kao, Wei‐Yu, Lin, Chih‐Lin, Yang, Sheng‐Shun, Shih, Yu‐Lueng, Peng, Cheng‐Yuan, Lee, Fu‐Jen, Tsai, Ming‐Chang, Huang, Shang‐Chin, Su, Tung‐Hung, Tseng, Tai‐Chung, Liu, Chun‐Jen, Chen, Pei‐Jer, and Kao, Jia‐Horng

Subjects
HEPATITIS C, ANTIVIRAL agents, HEPATITIS C virus
Abstract

Early confirmation of sustained virologic response (SVR) or viral relapse after direct‐acting antivirals (DAAs) for hepatitis C virus (HCV) infection is essential based on public health perspectives, particularly for patients with high risk of nonadherence to posttreatment follow‐ups. A total of 1011 patients who achieved end‐of‐treatment virologic response, including 526 receiving fixed‐dose pangenotypic DAAs, and 485 receiving other types of DAAs, who had available off‐treatment weeks 4 and 12 serum HCV RNA data to confirm SVR at off‐treatment week 12 (SVR12) or viral relapse were included. The positive predictive value (PPV) and negative predictive value (NPV) of SVR4 to predict patients with SVR12 or viral relapse were reported. Furthermore, we analyzed the proportion of concordance between SVR12 and SVR24 in 943 patients with available SVR24 data. The PPV and NPV of SVR4 to predict SVR12 were 98.5% (95% confidence interval [CI]: 98.0–98.9) and 100% (95% CI: 66.4–100) in the entire population. The PPV of SVR4 to predict SVR12 in patients receiving fixed‐dose pangenotypic DAAs was higher than those receiving other types of DAAs (99.8% [95% CI: 98.9–100] vs. 97.1% [95% CI: 96.2–97.8], p < 0.001). The NPVs of SVR4 to predict viral relapse were 100%, regardless of the type of DAAs. Moreover, the concordance between SVR12 and SVR24 was 100%. In conclusion, an off‐treatment week 4 serum HCV RNA testing is sufficient to provide an excellent prediction power of SVR or viral relapse at off‐treatment week 12 among patients with HCV who are treated with fixed‐dose pangenotypic DAAs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Author

Cheng, Xiaoming, Uchida, Takuro, Xia, Yuchen, Umarova, Regina, Liu, Chun-Jen, Chen, Pei-Jer, Gaggar, Anuj, Suri, Vithika, Mucke, Marcus M., Vermehren, Johannes, Zeuzem, Stefan, Teraoka, Yuji, Osawa, Mitsutaka, Aikata, Hiroshi, Tsuji, Keiji, Mori, Nami, Hige, Shuhei, Karino, Yoshiyasu, Imamura, Michio, Chayama, Kazuaki, and Liang, T. Jake

Subjects
United States. Food and Drug Administration, Sofosbuvir -- Health aspects, Backup software -- Health aspects, Biological response modifiers -- Health aspects, Medical research -- Health aspects, Infection -- Health aspects, Hepatitis C virus -- Health aspects, Interferon -- Health aspects, Comorbidity -- Health aspects, Hepatitis B -- Health aspects, Backup software, Health care industry
Abstract

In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied the molecular mechanisms behind this viral interaction. In coinfected cell culture and humanized mice, HBV replication was suppressed by HCV coinfection. In vitro, HBV suppression was attenuated when interferon (IFN) signaling was blocked. In vivo, HBV viremia, after initial suppression by HCV superinfection, rebounded following HCV clearance by DAA treatment that was accompanied by a reduced hepatic IFN response. Using blood samples of coinfected patients, IFN-stimulated gene products including C-X-C motif chemokine 10 (CXCL10), C-C motif chemokine ligand 5 (CCL5), and alanine aminotransferase (ALT) were identified to have predictive value for HBV reactivation after HCV clearance. Taken together, our data suggest that HBV reactivation is a result of diminished hepatic IFN response following HCV clearance and identify serologic markers that can predict HBV reactivation in DAA-treated HBV-HCV-coinfected persons., Introduction Hepatitis B virus (HBV) and hepatitis C virus (HCV) together infect more than 300 million people worldwide. Due to the shared modes of transmission and epidemiological features, they frequently [...]

Published
2020
Full Text
View/download PDF

46. Serum RNase L levels in patients with chronic hepatitis B virus infection.

Author

Chen, Chi‐Ling, Tseng, Tai‐Chung, Liu, Chun‐Jen, Kao, Jia‐Horng, Chen, Pei‐Jer, and Yang, Wei‐Shiung

Subjects
HEPATITIS B, CHRONIC hepatitis B, HEPATITIS B virus, CIRRHOSIS of the liver
Abstract

Background/Aims: Chronic hepatitis B virus (HBV) infection still poses a major threat to global health. Oligoadenylate synthetase–ribonuclease L (RNase L) antiviral pathway is one of interferon‐induced antiviral effectors. The relationship between RNase L and HBV has never been investigated and we aim to examine the serum RNase L levels in patients with different stages of chronic HBV infection. Methods: The patients were enrolled from 1985 to 2000, who had been HBsAg positive for longer than 6 months, at the National Taiwan University Hospital. In total, 426 patients with chronic HBV infection were included in this study, including 135 inactive carriers, 148 cirrhosis, and 143 hepatocellular carcinoma (HCC) cases. Results: The RNase L levels increase as the disease severity increases. Higher RNase L levels were associated with higher HBV viral load, and the HBV‐RNase L relationship was replaced by the disease severity status when adding disease status into the model. Compared with inactive carriers, the risk of liver cirrhosis was 60‐fold (odds ratio = 60.8, 95% confidence interval = 3.49–1061) with the highest quintile of RNase L levels, after the adjustment of HBV DNA. The dose–response trend was statistically significant with quintiles and one increment of RNase L level in relation to liver cirrhosis. Similar results were found when HCC was compared with inactive carriers, while there was no association when compared between liver cirrhosis and HCC. Conclusions: A positive relationship between serum RNase L and HBV viral titers or advanced disease status is uncovered in this study. Further investigation in this area may provide more details of an innate immune response for HBV and opportunity for novel therapeutic strategy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

Author

Liu, Chun-Jen, Chuang, Wan-Long, Sheen, I-Shyan, Wang, Horng-Yuan, Chen, Chi-Yi, Tseng, Kuo-Chih, Chang, Ting-Tsung, Massetto, Benedetta, Yang, Jenny C., Yun, Chohee, Knox, Steven J., Osinusi, Anu, Camus, Gregory, Jiang, Deyuan, Brainard, Diana M., McHutchison, John G., Hu, Tsung-Hui, Hsu, You-Chun, Lo, Gin-Ho, Chu, Chi-Jen, Chen, Jyh-Jou, Peng, Cheng-Yuan, Chien, Ron-Nan, and Chen, Pei-Jer

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results